LAURUS LABS Financial Statement Analysis
|
||
|
The Revenues of LAURUS LABS have increased by 10.18% YoY .
The Earnings Per Share (EPS) of LAURUS LABS has increased by 126.62 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
LAURUS LABS Last 5 Annual Financial Results
[BOM: 540222|NSE : LAURUSLABS]
| Consolidated | Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 |
|---|---|---|---|---|---|
| Revenues | ₹5,554 Cr | ₹5,041 Cr | ₹6,041 Cr | ₹4,936 Cr | ₹4,814 Cr |
| Expenses | ₹4,499 Cr | ₹4,263 Cr | ₹4,448 Cr | ₹3,513 Cr | ₹3,263 Cr |
| Operating Profit (Excl OI) | ₹1,055 Cr | ₹778 Cr | ₹1,592 Cr | ₹1,422 Cr | ₹1,551 Cr |
| Other Income | ₹75 Cr | ₹26 Cr | ₹6.00 Cr | ₹15 Cr | ₹24 Cr |
| Interest | ₹216 Cr | ₹183 Cr | ₹165 Cr | ₹102 Cr | ₹68 Cr |
| Depreciation | ₹430 Cr | ₹385 Cr | ₹324 Cr | ₹251 Cr | ₹205 Cr |
| Profit Before Tax | ₹484 Cr | ₹236 Cr | ₹1,109 Cr | ₹1,084 Cr | ₹1,301 Cr |
| Profit After Tax | ₹354 Cr | ₹168 Cr | ₹797 Cr | ₹832 Cr | ₹984 Cr |
| Consolidated Net Profit | ₹358 Cr | ₹158 Cr | ₹785 Cr | ₹828 Cr | ₹984 Cr |
| Earnings Per Share (Rs) | ₹6.64 | ₹2.93 | ₹14.56 | ₹15.40 | ₹18.33 |
| PAT Margin (%) | 6.38 | 3.34 | 13.19 | 16.87 | 20.44 |
| ROE(%) | 8.30 | 4.15 | 21.63 | 28.05 | 45.15 |
| ROCE(%) | 10.16 | 6.64 | 22.97 | 25.97 | 39.82 |
| Total Debt/Equity(x) | 0.61 | 0.61 | 0.49 | 0.52 | 0.56 |
Key Financials |
||
| Market Cap | : | ₹ 55,391.0 Cr |
| Revenue (TTM) | : | ₹ 6,358.4 Cr |
| Net Profit(TTM) | : | ₹ 679.3 Cr |
| EPS (TTM) | : | ₹ 12.6 |
| P/E (TTM) | : | 81.5 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| LAURUS LABS | -0.3% | 4.8% | 74.4% |
| SUN PHARMACEUTICAL INDUSTRIES | -0.2% | 7.1% | 1.1% |
| DIVIS LABORATORIES | 0.8% | -6% | 4.2% |
| CIPLA | -0.2% | 1.4% | -0.9% |
| TORRENT PHARMACEUTICALS | 1.2% | 6.4% | 13.1% |
| DR REDDYS LABORATORIES | 1.2% | 5.8% | 4.2% |
| MANKIND PHARMA | -1.1% | -4.5% | -13.7% |
| ZYDUS LIFESCIENCES | -0.5% | -0.5% | -4.8% |
| LUPIN | 0.5% | 7.2% | 0.5% |
LAURUS LABS Revenues
[BOM: 540222|NSE : LAURUSLABS]
| Y-o-Y | 10.18 % |
| 5 Yr CAGR | 3.64 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2025 | ₹5,554 Cr | 10.18 | |
| Mar2024 | ₹5,041 Cr | -16.55 | |
| Mar2023 | ₹6,041 Cr | 22.39 | |
| Mar2022 | ₹4,936 Cr | 2.54 | |
| Mar2021 | ₹4,814 Cr | - | |
LAURUS LABS Operating Profit
[BOM: 540222|NSE : LAURUSLABS]
| Y-o-Y | 35.73 % |
| 5 Yr CAGR | -9.17 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹1,055 Cr | 35.73 | |
| Mar2024 | ₹778 Cr | -51.17 | |
| Mar2023 | ₹1,592 Cr | 11.93 | |
| Mar2022 | ₹1,422 Cr | -8.27 | |
| Mar2021 | ₹1,551 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 23.22 % |
| 5 Yr CAGR | -12.37 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2025 | 19% | 23.22 | |
| Mar2024 | 15.42% | -41.50 | |
| Mar2023 | 26.36% | -8.54 | |
| Mar2022 | 28.82% | -10.55 | |
| Mar2021 | 32.22% | - | |
LAURUS LABS Profit After Tax
[BOM: 540222|NSE : LAURUSLABS]
| Y-o-Y | 127.25 % |
| 5 Yr CAGR | -22.31 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2025 | ₹358 Cr | 127.25 | |
| Mar2024 | ₹158 Cr | -79.90 | |
| Mar2023 | ₹785 Cr | -5.20 | |
| Mar2022 | ₹828 Cr | -15.87 | |
| Mar2021 | ₹984 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 91.02 % |
| 5 Yr CAGR | -25.25 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2025 | 6.38 % | 91.02 | |
| Mar2024 | 3.34 % | -74.68 | |
| Mar2023 | 13.19 % | -21.81 | |
| Mar2022 | 16.87 % | -17.47 | |
| Mar2021 | 20.44 % | - | |
LAURUS LABS Earnings Per Share (EPS)
[BOM: 540222|NSE : LAURUSLABS]
| Y-o-Y | 126.62 % |
| 5 Yr CAGR | -22.42 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2025 | ₹6.64 | 126.62 | |
| Mar2024 | ₹2.93 | -79.88 | |
| Mar2023 | ₹15 | -5.45 | |
| Mar2022 | ₹15 | -15.98 | |
| Mar2021 | ₹18 | - | |
LAURUS LABS Return on Capital Employed (ROCE)
[BOM: 540222|NSE : LAURUSLABS]
| Y-o-Y | 53.01 % |
| 5 Yr CAGR | -28.93 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2025 | 10.16% | 53.01 | |
| Mar2024 | 6.64% | -71.09 | |
| Mar2023 | 22.97% | -11.55 | |
| Mar2022 | 25.97% | -34.78 | |
| Mar2021 | 39.82% | - | |
LAURUS LABS Share Price vs Sensex
| Current Share Price | : | ₹1,026.0 |
| Current MarketCap | : | ₹ 55,391.0 Cr |
| Updated EOD on | : | Dec 05,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| LAURUS LABS | -0.3% |
4.8% |
74.4% |
| SENSEX | 0% |
2.7% |
6.8% |
LAURUS LABS related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% |
| BSE MIDSMALLCAP | 4.7% | 9% | 8.4% |
| BSE LARGEMIDCAP | 4.5% | 7.2% | 8.3% |
| BSE 500 SHARIAH | 4.3% | 4.3% | 1.1% |
| BSE 500 | -0.4% | 0.7% | 4% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY PHARMA | -0.2% | 2.7% | 2.2% |
| NIFTY MIDSMALL HEALTHCARE | -0.4% | -1.1% | 3.2% |
| NIFTY 500 | -0.4% | 0.7% | 4.4% |
| NIFTY TOTAL MARKET | -0.5% | 0.4% | 3.8% |
| NIFTY500 MULTICAP 50:25:25 | -0.6% | -0.3% | 2.5% |
You may also like the below Video Courses
FAQ about LAURUS LABS Financials
How the annual revenues of LAURUS LABS have changed ?
The Revenues of LAURUS LABS have increased by 10.18% YoY .
How the Earnings per Share (EPS) of LAURUS LABS have changed?
The Earnings Per Share (EPS) of LAURUS LABS has increased by 126.62 % YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs